The large number of biologic drug patents in the United States has contributed to delays in biosimilar availability.
Biologic drugs such as monoclonal antibodies and gene therapies have become mainstays in the treatment of many diseases, but also focal points in the debate over pharmaceutical pricing. Biologics accounted for 48% of net manufacturer revenue and 43% of total medicine spending in the United States in 2019, and have been forecasted for continued rapid growth1. Derived from living systems, they are more difficult to produce than small-molecule drugs. Biologics are also more expensive. Many of the most widely used biologics have annual net prices of more than US$30,000 per year, including the monoclonal antibodies intended to treat inflammatory diseases: Humira (adalimumab, US$39,751), Cimiza (certolizumab, US$48,193) and Enbrel (etanercept, US$43,910)2. These high prices have placed increasing strain on the healthcare system as biologics have increased as a proportion of new drug approvals. Between 1996 and 2000, 14% of US Food and Drug Administration (FDA)-approved new drugs were biologics; by contrast, between 2016 and 2020, 26% were biologics3.
This is a preview of subscription content
Access options
Subscribe to Journal
Get full journal access for 1 year
92,52 €
only 7,71 € per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
References
- 1.
Biosimilars in the United States: Competition, Savings, and Sustainability (IQVIA, 2020); https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/iqvia-institute-biosimilars-in-the-united-states.pdf
- 2.
Ferris, L. K., Gellad, W. F. & Hernandez, I. JAMA Dermatol. 156, 1136–1138 (2020).
- 3.
Compilation of CDER New Molecular Entity (NME) Drug and New Biologic Approvals (FDA, accessed 6 August 2021); https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process
- 4.
Sarpatwari, A., Barenie, R. & Curfman, G. Clin. Pharmacol. Ther. 105, 92–100 (2019).
- 5.
FDA approvals. Big Molecule Watch (accessed 29 December 2021); https://www.bigmoleculewatch.com/fda-approved-ablas/
- 6.
Biosimilar approval status. Biosimilars Review and Report (accessed 23 December 2021); https://biosimilarsrr.com/us-biosimilar-filings/
- 7.
Medicines (EMA, accessed 23 December 2021); https://www.ema.europa.eu/en/medicines
- 8.
Overpatented, Overpriced: How Excessive Pharmaceutical Patenting is Extending Monopolies and Driving up Drug Prices (IMAK, 2018); https://www.i-mak.org/wp-content/uploads/2018/08/I-MAK-Overpatented-Overpriced-Report.pdf
- 9.
Druedahl, L. C. et al. Nat. Biotechnol. 38, 1253–1256 (2020).
- 10.
Van de Wiele, V. L., Kesselheim, A. S. & Sarpatwari, A. Health Aff. 40, 1198–1205 (2021).
- 11.
Price, W. N. & Rai, A. K. Iowa Law Rev. 101, 1023–1063 (2016).
- 12.
Drug Pricing and Pharmaceutical Patenting Practices (Congressional Research Service, 2020); https://fas.org/sgp/crs/misc/R46221.pdf
- 13.
BPCIA Litigations (Big Molecule Watch, accessed 13 May 2021); https://www.bigmoleculewatch.com/bpcia-patent-litigations/
- 14.
Patent Term Calculator (USPTO, accessed 6 August 2021); https://www.uspto.gov/patents/laws/patent-term-calculator
- 15.
Beall, R. F., Darrow, J. J. & Kesselheim, A. S. Value Health 21, 1382–1389 (2018).
- 16.
Vilcek, J. Nat. Immunol. 10, 555–557 (2009).
- 17.
Pelechas, E., Voulgari, P. V. & Drosos, A. A. Expert Opin. Drug Discov. 16, 227–234 (2021).
- 18.
Hemphill, C. S. & Sampat, B. Science 339, 1386–1387 (2013).
- 19.
Rai, A. K. & Price, W. N. II Nat. Biotechnol. 39, 20–22 (2021).
- 20.
Bergman, M., Patel, P., Chen, N., Jing, Y. & Saffore, C. D. Rheumatol. Ther. 8, 109–118 (2021).
- 21.
Chung, A. Europe issues better patents than US – Europe patent boss. Reuters (15 September 2016).
- 22.
Picard, P. M. & van Pottelsberghe de la Portterie, B. J. Public Econ. 104, 14–25 (2013).
- 23.
Moorkens, E., Vulto, A. G. & Huys, I. MAbs 12, 1743517 (2020).
- 24.
Feldman, R. Drugs, Money, and Secret Handshakes (Cambridge Univ. Press, 2019).
- 25.
Bloomfield, D. & Kesselheim, A.S. Biden can lower drug prices without Congress doing anything. Washington Post (5 January 2021).
- 26.
Frakes, M.D. & Wasserman, M.F. Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination (NBER, 2020); https://www.nber.org/papers/w27579
Acknowledgements
This work was supported by Arnold Ventures.
Ethics declarations
Competing interests
The authors declare no competing interests.
About this article
Cite this article
Van de Wiele, V.L., Beall, R.F., Kesselheim, A.S. et al. The characteristics of patents impacting availability of biosimilars.
Nat Biotechnol 40, 22–25 (2022). https://doi.org/10.1038/s41587-021-01170-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-021-01170-5
Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here
Amazon Basics XLR Microphone Cable for Speaker or PA System, All Copper Conductors, 6MM PVC Jacket, 6 Foot, Black
$9.11 (as of May 18, 2024 20:34 GMT +00:00 - More infoProduct prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on [relevant Amazon Site(s), as applicable] at the time of purchase will apply to the purchase of this product.)
[2024 Upgrade] Nmoiss Windshield Sun Shade Umbrella for Car - [Newest Vinyl Coating] Protect Car from Sun Rays & Heat Damage…
$39.98 (as of May 18, 2024 20:34 GMT +00:00 - More infoProduct prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on [relevant Amazon Site(s), as applicable] at the time of purchase will apply to the purchase of this product.)
2025 US RED BOOK of United States Coins and 1976 Ike Dollar US Mint Circ
$23.99 (as of May 18, 2024 20:34 GMT +00:00 - More infoProduct prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on [relevant Amazon Site(s), as applicable] at the time of purchase will apply to the purchase of this product.)
2024 S Proof Set US Mint Packaged
$45.95 (as of May 18, 2024 20:34 GMT +00:00 - More infoProduct prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on [relevant Amazon Site(s), as applicable] at the time of purchase will apply to the purchase of this product.)
